---
title: "Schisandra chinensis (Wu Wei Zi) - Evidence-Based Clinical Monograph"
category: "Herbal Medicine"
subcategory: "Adaptogenic & Hepatoprotective Herbs"
botanical_family: "Schisandraceae"
botanical_name: "Schisandra chinensis"
common_names: ["Schisandra", "Wu Wei Zi", "Omija", "Five Flavor Berry"]
primary_uses: ["hepatoprotection", "adaptogen", "cognitive enhancement", "physical performance", "liver disease"]
tags: ["schisandrin", "lignans", "hepatoprotective", "adaptogen", "neuroprotection", "CYP3A4", "drug interactions", "NAFLD", "cognitive function", "antioxidant"]
date: "2025-11-10"
evidence_quality: "High (Grade A-B for hepatoprotection, Grade B-C for cognitive)"
safety_profile: "Good - Grade B (with drug interaction precautions)"
source: "Evidence-based clinical research compilation with verified citations"
last_updated: "November 2025"
document_type: "Clinical Monograph"
target_audience: "Healthcare Practitioners"
version: "1.0"
study_count_by_type:
  sr_ma: 4
  rcts: 11
  observational: 2
  animal: 54
  in_vitro: 15
  traditional_use: 1
---

# Schisandra chinensis — Evidence-Based Clinical Monograph

**DOCUMENT CONTEXT:** This comprehensive clinical monograph provides healthcare professionals with evidence-based information on Schisandra chinensis (Wu Wei Zi). All citations have been verified with links to original research. Document optimized for vector store embedding with semantic structure and rich metadata.

**Document Purpose:** This monograph provides a comprehensive, evidence-based analysis of *Schisandra chinensis*, also known as Wu Wei Zi or Omija. The information presented adheres to a strict hierarchy of evidence, prioritizing systematic reviews, randomized controlled trials, and observational studies over preclinical data and traditional use. The goal is to deliver actionable clinical guidance for clinicians and researchers.

## [semantic_index] Semantic Index (Section Map)

- [pharmacology] Pharmacology & Mechanisms of Action
- [pharmacokinetics] Pharmacokinetics & Drug Interactions
- [clinical_evidence] Human Clinical Evidence Map
- [dosing] Dosing & Administration Protocols
- [safety] Safety Profile & Toxicology
- [quality] Quality Control & Adulteration
- [comparative] Comparative Analysis & Clinical Decision Rules
- [case_studies] Case Studies & Research Frontiers
- [red_flags] Red Flags & Triage Parameters
- [quality_checklist] Quality & Adulteration Checklist
- [audit] Source Audit Log

---

## Pharmacology & Mechanisms of Action

The diverse therapeutic properties of *Schisandra chinensis* are rooted in its complex phytochemical composition, which is dominated by dibenzocyclooctadiene lignans [[1](https://pmc.ncbi.nlm.nih.gov/articles/PMC8073495/), [7](https://cmjournal.biomedcentral.com/articles/10.1186/s13020-025-01096-z)]. These bioactive compounds mediate a wide array of pharmacological effects through the modulation of multiple cellular signaling pathways, primarily centered on the potentiation of endogenous antioxidant defenses and the suppression of inflammatory cascades. The herb's ability to enhance physical and mental endurance, protect against organ damage, and modulate immune responses stems directly from these fundamental biochemical actions [[5](https://www.mskcc.org/cancer-care/integrative-medicine/herbs/schisandra), [47](https://drruscio.com/schisandra-benefits/)].

The most abundant and extensively studied class of compounds in *Schisandra chinensis* are the dibenzocyclooctadiene lignans, which include schisandrin, schisandrin A, schisandrin B, schisandrin C, gomisin A, gomisin N, deoxyschizandrin, and schisantherin A [[1](https://pmc.ncbi.nlm.nih.gov/articles/PMC8073495/), [7](https://cmjournal.biomedcentral.com/articles/10.1186/s13020-025-01096-z), [18](https://www.drugs.com/npp/schisandra.html)]. Among these, schisandrin is often cited as the most dominant lignan, found in concentrations ranging from 2.2 to 5.3 mg/g of dried fruit [[1](https://pmc.ncbi.nlm.nih.gov/articles/PMC8073495/), [45](https://www.researchgate.net/publication/380447294_Schisandra_chinensis_in_Liver_Disease_Exploring_the_Mechanisms_and_Therapeutic_Promise_of_an_Ancient_Chinese_Botanical)]. Other significant components include polysaccharides, essential oils rich in sesquiterpenes, triterpenoids, flavonoids, and phenolic acids [[6](https://www.scientificarchives.com/article/schisandra-chinensis-in-liver-disease-exploring-the-mechanisms-and-therapeutic-promise-of-an-ancient-chinese-botanical), [45](https://www.researchgate.net/publication/380447294_Schisandra_chinensis_in_Liver_Disease_Exploring_the_Mechanisms_and_Therapeutic_Promise_of_an_Ancient_Chinese_Botanical)]. While all contribute to the overall effect, the lignans are considered the principal mediators of the plant's adaptogenic, hepatoprotective, neuroprotective, and immunomodulatory activities [[7](https://cmjournal.biomedcentral.com/articles/10.1186/s13020-025-01096-z)].

A primary mechanism of action involves the robust enhancement of the body's intrinsic antioxidant systems. Preclinical studies consistently demonstrate that *Schisandra* extracts significantly increase the activity of key antioxidant enzymes, such as superoxide dismutase (SOD) and glutathione peroxidase (GPx), while elevating levels of the crucial antioxidant molecule, reduced glutathione (GSH) [[1](https://pmc.ncbi.nlm.nih.gov/articles/PMC8073495/), [10](https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1627081/full), [61](https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1627081/pdf)]. Concurrently, it reduces the accumulation of malondialdehyde (MDA), a reliable biomarker of lipid peroxidation and oxidative stress [[1](https://pmc.ncbi.nlm.nih.gov/articles/PMC8073495/), [10](https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1627081/full), [61](https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1627081/pdf)]. This dual action is mechanistically linked to the activation of the nuclear factor erythroid 2-related factor 2 (Nrf2)/antioxidant response element (ARE) signaling pathway [[10](https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1627081/full), [27](https://www.mdpi.com/2297-8739/11/3/88)]. By upregulating genes controlled by Nrf2, such as heme oxygenase-1 (HO-1), NAD(P)H quinone dehydrogenase 1 (NQO1), and glutamate-cysteine ligase modifier subunit (GCLM), *Schisandra* fortifies cellular defense against reactive oxygen species (ROS) [[10](https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1627081/full), [27](https://www.mdpi.com/2297-8739/11/3/88)]. For instance, schisandrin B has been shown to possess strong ROS scavenging ability, comparable to vitamin C, and to protect human blood lymphocytes from oxidative DNA damage [[1](https://pmc.ncbi.nlm.nih.gov/articles/PMC8073495/)]. This powerful antioxidant capacity underpins its protective effects in conditions characterized by oxidative stress, including liver injury, cardiomyopathy, and neurodegeneration [[1](https://pmc.ncbi.nlm.nih.gov/articles/PMC8073495/), [5](https://www.mskcc.org/cancer-care/integrative-medicine/herbs/schisandra)].

Simultaneously, *Schisandra* exerts significant anti-inflammatory effects by modulating key inflammatory signaling pathways. It effectively suppresses the activation of the nuclear factor-kappa B (NF-κB) pathway, a master regulator of inflammation, thereby downregulating the expression of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and interleukin-1 beta (IL-1β) [[7](https://cmjournal.biomedcentral.com/articles/10.1186/s13020-025-01096-z), [10](https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1627081/full), [45](https://www.researchgate.net/publication/380447294_Schisandra_chinensis_in_Liver_Disease_Exploring_the_Mechanisms_and_Therapeutic_Promise_of_an_Ancient_Chinese_Botanical)]. Inhibition of mitogen-activated protein kinase (MAPK) pathways, including p38 and JNK, further contributes to its anti-inflammatory profile [[1](https://pmc.ncbi.nlm.nih.gov/articles/PMC8073495/), [7](https://cmjournal.biomedcentral.com/articles/10.1186/s13020-025-01096-z)]. Lignans like schisandrin and schisandrol A have been shown to inhibit nitric oxide (NO) and prostaglandin E2 (PGE2) production by suppressing inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) expression in stimulated macrophages [[7](https://cmjournal.biomedcentral.com/articles/10.1186/s13020-025-01096-z), [66](https://journals.athmsi.org/index.php/ajtcam/article/download/2211/1726/6576)]. This multifaceted anti-inflammatory action is central to its efficacy in treating conditions like hepatitis, dermatitis, and osteoarthritis [[5](https://www.mskcc.org/cancer-care/integrative-medicine/herbs/schisandra), [6](https://www.scientificarchives.com/article/schisandra-chinensis-in-liver-disease-exploring-the-mechanisms-and-therapeutic-promise-of-an-ancient-chinese-botanical)].

In the context of hepatoprotection, *Schisandra*'s mechanisms are particularly well-characterized. It protects hepatocytes from xenobiotic-induced injury through several interconnected processes. Firstly, it modulates the activity of hepatic cytochrome P450 enzymes, particularly CYP3A and CYP2E1, which are involved in the bioactivation of toxins like acetaminophen into their toxic metabolites [[7](https://cmjournal.biomedcentral.com/articles/10.1186/s13020-025-01096-z), [41](https://www.sciencedirect.com/topics/medicine-and-dentistry/gomisin-a)]. Secondly, it enhances the synthesis and regeneration of hepatic GSH, the primary intracellular antioxidant that detoxifies these harmful intermediates [[2](https://www.webmd.com/vitamins/ai/ingredientmono-376/schisandra), [41](https://www.sciencedirect.com/topics/medicine-and-dentistry/gomisin-a)]. Thirdly, it stimulates the proliferation of hepatocytes and improves hepatic blood flow, promoting tissue repair and regeneration [[7](https://cmjournal.biomedcentral.com/articles/10.1186/s13020-025-01096-z), [41](https://www.sciencedirect.com/topics/medicine-and-dentistry/gomisin-a)]. Furthermore, it exhibits anti-apoptotic effects by modulating the balance of Bcl-2 family proteins (upregulating anti-apoptotic Bcl-2, downregulating pro-apoptotic Bax) and inhibiting caspase activation [[10](https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1627081/full), [41](https://www.sciencedirect.com/topics/medicine-and-dentistry/gomisin-a)]. The combined effect of these actions—reducing toxin formation, enhancing detoxification, promoting cell survival, and stimulating regeneration—results in the clinically observed reduction of serum transaminases (ALT and AST) in patients with liver damage [[5](https://www.mskcc.org/cancer-care/integrative-medicine/herbs/schisandra), [63](https://journals.lww.com/stcm/fulltext/2025/03000/effects_of_schisandrae_fructus_alone_or_in.8.aspx)].

For neurological applications, the mechanisms are equally intricate. *Schisandra* lignans cross the blood-brain barrier (BBB), with schisandrin B, schisandrin A, and gomisin A being identified as BBB-permeable compounds [[7](https://cmjournal.biomedcentral.com/articles/10.1186/s13020-025-01096-z)]. Once in the brain, they exert neuroprotection by mitigating oxidative stress, suppressing neuroinflammation, and protecting neurons from amyloid-beta (Aβ) toxicity [[1](https://pmc.ncbi.nlm.nih.gov/articles/PMC8073495/), [7](https://cmjournal.biomedcentral.com/articles/10.1186/s13020-025-01096-z)]. Critically, multiple studies in animal models have demonstrated that *Schisandra* treatment upregulates the expression of Brain-Derived Neurotrophic Factor (BDNF) and activates its downstream signaling pathways, including TrkB/CREB/ERK and PI3K/AKT/GSK-3β [[11](https://www.nature.com/articles/s41598-017-07407-1), [22](https://www.sciencedirect.com/science/article/pii/S2405844023091508), [24](https://www.cell.com/heliyon/fulltext/S2405-8440(23)09150-8)]. This enhancement of neurotrophic support is believed to be a primary mechanism for its antidepressant-like and cognition-enhancing effects [[11](https://www.nature.com/articles/s41598-017-07407-1)]. Network pharmacology analyses further suggest that its bioactive components interact with targets in the cholinergic synapse, potentially by inhibiting acetylcholinesterase (AChE), which could explain improvements in memory and cognitive performance [[62](https://pmc.ncbi.nlm.nih.gov/articles/PMC11547720/)].

Finally, *Schisandra* demonstrates immunomodulatory and anticancer properties. It can modulate immune responses, as seen in the anti-colitis effects mediated by gut microbiota modulation [[6](https://www.scientificarchives.com/article/schisandra-chinensis-in-liver-disease-exploring-the-mechanisms-and-therapeutic-promise-of-an-ancient-chinese-botanical)], and reverse multidrug resistance in cancer cells [[5](https://www.mskcc.org/cancer-care/integrative-medicine/herbs/schisandra)]. Certain lignans, such as gomisin A, can inhibit P-glycoprotein (P-gp), an efflux pump that expels chemotherapeutic agents from cancer cells, thereby sensitizing tumors to drugs like doxorubicin [[1](https://pmc.ncbi.nlm.nih.gov/articles/PMC8073495/), [5](https://www.mskcc.org/cancer-care/integrative-medicine/herbs/schisandra)]. Additionally, *Schisandra* lignans induce apoptosis and cell cycle arrest in various cancer cell lines [[1](https://pmc.ncbi.nlm.nih.gov/articles/PMC8073495/), [7](https://cmjournal.biomedcentral.com/articles/10.1186/s13020-025-01096-z)]. The structural features of the lignans themselves dictate their biological activity; for example, a methylenedioxy group is necessary for antioxidant activity, while a hydroxyl group at a specific position can decrease it [[1](https://pmc.ncbi.nlm.nih.gov/articles/PMC8073495/)]. This structure-activity relationship highlights the precision with which these molecules interact with biological targets.

#### Bottom Line
The pharmacological actions of *Schisandra chinensis* are mediated primarily by dibenzocyclooctadiene lignans that confer broad-spectrum protection against oxidative stress and inflammation. Its core mechanisms involve the activation of the Nrf2 antioxidant pathway, suppression of NF-κB-mediated inflammation, and modulation of neurotrophic factors like BDNF. These multi-targeted effects provide a strong scientific basis for its traditional uses and its emerging applications in modern medicine.

---

## Pharmacokinetics & Drug Interactions

The clinical utility and safety of *Schisandra chinensis* are profoundly influenced by its complex pharmacokinetic profile and its potent, dose- and duration-dependent interactions with key drug-metabolizing enzymes and transporters. Understanding these dynamics is paramount for predicting and preventing adverse drug-herb interactions. The primary culprits for these interactions are the dibenzocyclooctadiene lignans, which exhibit poor water solubility and undergo extensive first-pass metabolism, leading to low systemic bioavailability when administered as isolated compounds but enhanced absorption within the herbal matrix [[7](https://cmjournal.biomedcentral.com/articles/10.1186/s13020-025-01096-z), [33](https://pmc.ncbi.nlm.nih.gov/articles/PMC6017025/)].

The oral bioavailability of schisandrin, a major lignan, is remarkably low when administered as a pure compound in rats, estimated at approximately 15.56% [[1](https://pmc.ncbi.nlm.nih.gov/articles/PMC8073495/), [33](https://pmc.ncbi.nlm.nih.gov/articles/PMC6017025/)]. However, when administered as part of the whole *Schisandra chinensis* extract, its bioavailability dramatically increases to 37.59–78.42%, suggesting that other components of the herbal matrix may enhance its absorption [[33](https://pmc.ncbi.nlm.nih.gov/articles/PMC6017025/)]. Similarly, the absolute oral bioavailability of schisandrin B shows a marked sex-dependent difference in rats, with females exhibiting ~55% bioavailability compared to only ~19% in males [[1](https://pmc.ncbi.nlm.nih.gov/articles/PMC8073495/), [7](https://cmjournal.biomedcentral.com/articles/10.1186/s13020-025-01096-z)]. After oral administration of the herbal extract, schisandrin reaches peak plasma concentrations (Cmax) around 185-200 minutes post-dose, with a mean residence time (MRT) of over 200 minutes, indicating slow absorption and prolonged presence in circulation [[33](https://pmc.ncbi.nlm.nih.gov/articles/PMC6017025/)]. The pharmacokinetics of these lignans are nonlinear, likely due to saturation of metabolic enzymes during first-pass metabolism in the liver and gastrointestinal wall [[33](https://pmc.ncbi.nlm.nih.gov/articles/PMC6017025/)].

The most significant clinical concern arises from *Schisandra*'s profound impact on the cytochrome P450 (CYP) enzyme system, particularly CYP3A4, which is responsible for metabolizing over 50% of all clinically used drugs [[5](https://www.mskcc.org/cancer-care/integrative-medicine/herbs/schisandra)]. The evidence for this interaction is overwhelming and consistent across multiple study types. In vitro studies using human liver microsomes have unequivocally identified numerous *Schisandra* lignans as potent inhibitors of CYP3A4. Gomisin C, for example, acts as a competitive inhibitor with a Ki value (inhibition constant) of 0.049 µM, making it more potent than the prescription inhibitor ketoconazole (Ki = 0.070 µM) [[20](https://pubmed.ncbi.nlm.nih.gov/15342469/)]. Other lignans, including schisandrin B, schisandrol A, and gomisin A, also demonstrate strong inhibitory effects [[5](https://www.mskcc.org/cancer-care/integrative-medicine/herbs/schisandra), [12](https://pmc.ncbi.nlm.nih.gov/articles/PMC8000448/), [16](https://khu.elsevierpure.com/en/publications/inhibitory-effects-of-schisandra-lignans-on-cytochrome-p450s-and-)]. Crucially, some of these lignans, such as gomisin A, act via time-dependent inhibition, also known as mechanism-based inactivation [[12](https://pmc.ncbi.nlm.nih.gov/articles/PMC8000448/), [16](https://khu.elsevierpure.com/en/publications/inhibitory-effects-of-schisandra-lignans-on-cytochrome-p450s-and-)]. This process involves the metabolic activation of the lignan itself into a reactive intermediate that forms a stable, long-lasting complex with the CYP3A4 enzyme, irreversibly inactivating it until new enzyme is synthesized [[20](https://pubmed.ncbi.nlm.nih.gov/15342469/)]. This mechanism poses a greater risk for sustained drug interactions compared to simple competitive inhibition.

This potent in vitro inhibition translates directly into clinically significant drug interactions in vivo. A landmark randomized, double-blind, placebo-controlled trial in healthy volunteers co-administered *Schisandra sphenanthera* extract (which contains similar lignans) with midazolam, a classic probe substrate for CYP3A4 [[35](https://pmc.ncbi.nlm.nih.gov/articles/PMC2686071/)]. The results were dramatic: the area under the curve (AUC), a measure of total drug exposure, was increased by 119.4%, and the maximum plasma concentration (Cmax) was increased by 85.6% [[35](https://pmc.ncbi.nlm.nih.gov/articles/PMC2686071/)]. According to FDA criteria, this level of inhibition constitutes a moderate-to-strong interaction, capable of increasing the risk of adverse effects from co-administered CYP3A4 substrate drugs [[35](https://pmc.ncbi.nlm.nih.gov/articles/PMC2686071/)]. Similar findings have been reported for tacrolimus, an immunosuppressant whose bioavailability is significantly increased by *Schisandra* preparations, necessitating careful dose adjustments in transplant recipients [[2](https://www.webmd.com/vitamins/ai/ingredientmono-376/schisandra), [5](https://www.mskcc.org/cancer-care/integrative-medicine/herbs/schisandra), [18](https://www.drugs.com/npp/schisandra.html)]. Physiologically-based pharmacokinetic (PBPK) modeling corroborates these findings, predicting substantial increases in the exposure of tacrolimus when co-administered with lignans like schisantherin A and schisandrin B [[6](https://www.scientificarchives.com/article/schisandra-chinensis-in-liver-disease-exploring-the-mechanisms-and-therapeutic-promise-of-an-ancient-chinese-botanical), [37](https://www.mdpi.com/1422-0067/23/9/4485)].

Beyond CYP3A4, *Schisandra* lignans also inhibit other relevant CYP isoforms. In vitro studies show potent inhibition of CYP2C8, CYP2C9, and CYP2C19 by lignans like gomisin A [[12](https://pmc.ncbi.nlm.nih.gov/articles/PMC8000448/), [16](https://khu.elsevierpure.com/en/publications/inhibitory-effects-of-schisandra-lignans-on-cytochrome-p450s-and-)]. Gomisin A, in particular, has been shown to strongly inhibit CYP2C8, CYP2C19, and CYP3A4 in a time-dependent manner [[12](https://pmc.ncbi.nlm.nih.gov/articles/PMC8000448/), [16](https://khu.elsevierpure.com/en/publications/inhibitory-effects-of-schisandra-lignans-on-cytochrome-p450s-and-)]. This suggests a broader interaction potential beyond just CYP3A4 substrates. The clinical relevance of inhibiting these enzymes remains undetermined but warrants caution, especially with narrow-therapeutic-index drugs metabolized by these pathways [[5](https://www.mskcc.org/cancer-care/integrative-medicine/herbs/schisandra)].

A critical nuance complicating the clinical picture is that chronic administration of *Schisandra* may induce CYP3A4 expression. Animal studies in rats have shown that multiple oral doses of *Schisandra* extract lead to an induction of CYP3A1/2 enzyme activity and protein expression [[13](https://www.sciencedirect.com/science/article/abs/pii/S0378874114005455), [39](https://pubmed.ncbi.nlm.nih.gov/19741040/)]. This creates a complex, biphasic interaction profile where short-term co-administration leads to inhibition, but long-term use could result in net induction, potentially accelerating the metabolism of co-administered drugs [[13](https://www.sciencedirect.com/science/article/abs/pii/S0378874114005455)]. This makes it exceptionally difficult to predict the net effect of *Schisandra* on drug disposition in patients taking it chronically, reinforcing the principle of extreme caution.

Another important interaction occurs with P-glycoprotein (P-gp), an ATP-binding cassette (ABC) transporter that actively pumps drugs out of cells, limiting their absorption and promoting their excretion. *Schisandra* has been shown to inhibit P-gp activity [[5](https://www.mskcc.org/cancer-care/integrative-medicine/herbs/schisandra), [18](https://www.drugs.com/npp/schisandra.html)]. This inhibition synergizes with CYP3A4 inhibition, as both enzymes are located in the intestinal epithelium and work together to reduce the bioavailability of many drugs. By blocking both the metabolic breakdown (by CYP3A4) and the efflux (by P-gp) of a drug, *Schisandra* can dramatically increase its systemic exposure. Clinical evidence confirms this, with one study showing that a 14-day course of *S. chinensis* inhibited P-gp, leading to a 1.5-fold increase in the AUC of talinolol, a P-gp probe substrate [[18](https://www.drugs.com/npp/schisandra.html)]. This dual blockade of metabolic and transport pathways represents a significant risk for potentiation of drug effects.

#### Bottom Line
*Schisandra chinensis* possesses a complex pharmacokinetic profile characterized by variable and nonlinear absorption of its lignan constituents. Its most clinically significant property is its potent inhibition of CYP3A4, primarily through mechanism-based inactivation, and its inhibition of P-glycoprotein. This dual action substantially increases the bioavailability and exposure of co-administered drugs metabolized by these pathways, creating a high risk of severe adverse events. Chronic use may introduce additional complexity through potential CYP3A4 induction, making predictable outcomes challenging. This robust interaction potential is the single most important consideration for safe clinical application.

---

## Human Clinical Evidence Map

The clinical evidence for *Schisandra chinensis* spans a range of indications, from well-supported hepatoprotection to emerging benefits in metabolic and musculoskeletal health. The quality of evidence varies, with some areas supported by large-scale meta-analyses and others by smaller, single trials. The following table synthesizes the available human clinical data according to the specified evidence grading rubric, providing a clear overview of the strength of evidence for each indication.

| Indication | Grade | Best Study Type | n | Dose/Form | Duration | Primary Outcome | Effect Size (CI/p) | Key PMIDs |
| :--- | :--- | :--- | ---: | :--- | :--- | :--- | :--- | :--- |
| **Hepatoprotection** | A | Systematic Review/Meta-analysis | 2,766 | SF-containing formulas / Extracts | 6 weeks - 7.1 months | Reduction in ALT/AST | WMD: ALT↓18.45 U/L, AST↓8.37 U/L | [[63](https://journals.lww.com/stcm/fulltext/2025/03000/effects_of_schisandrae_fructus_alone_or_in.8.aspx)] |
| Hepatoprotection | A | Systematic Review/Meta-analysis | 1,314 | Fruit extract / Lignans | Not specified | Reduction in ALT/AST | SMD: ALT↓-5.10, AST↓-4.74 | [[10](https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1627081/full), [61](https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1627081/pdf)] |
| Hepatoprotection | B | Randomized Controlled Trial | 247 | SF powder + antiviral | 48 weeks | Improvement in histologic NASH | OR: 43% vs 19% (placebo) | [[65](https://pubmed.ncbi.nlm.nih.gov/20427778/)] |
| Adaptogenic Effects (Muscle Strength) | B | Randomized Controlled Trial | 45 | Extract (1000 mg/day) | 12 weeks | Increase in quadriceps strength | p=0.001 vs placebo | [[8](https://pmc.ncbi.nlm.nih.gov/articles/PMC7177795/), [56](https://www.mdpi.com/1660-4601/17/7/2475)] |
| Adaptogenic Effects (Muscle Strength) | B | Randomized Controlled Trial | 54 | Extract (1000 mg/day) | 12 weeks | Increase in knee extensor strength | Mean diff: 10.2 Nm (95% CI: 3.7 to 16.8) | [[50](https://www.sciencedirect.com/science/article/pii/S0002916522007237)] |
| Menopausal Symptoms | B | Randomized Controlled Trial | 36 | Extract (BMO-30) | 6 weeks | Reduction in Kupperman Index | p=0.042 vs placebo | [[58](https://pubmed.ncbi.nlm.nih.gov/27763802/), [60](https://www.researchgate.net/publication/309342787_A_randomized_double-blind_placebo-controlled_trial_of_Schisandra_chinensis_for_menopausal_symptoms)] |
| Menopausal Symptoms | B | Randomized Controlled Trial | 36 | Extract (392 mg twice daily) | 12 weeks | Improvement in hot flushes, sweating, palpitations | p<0.05 | [[18](https://www.drugs.com/npp/schisandra.html)] |
| Hyperglycemia/Prediabetes | C | Randomized Controlled Trial | 63 | Omija/Soybean mixture (500 mg/day) | 12 weeks | Reduction in fasting plasma glucose | Change: -5.62 vs +0.66 mg/dL (p=0.020) | [[9](https://www.mdpi.com/2072-6643/14/15/3159)] |
| Hyperglycemia/Prediabetes | C | Randomized Controlled Trial | 28 | Powder (6.7 g/day) | 12 weeks | Improvement in gut microbiota diversity | Not specified | [[47](https://drruscio.com/schisandra-benefits/)] |
| Cognitive Function | D | Double-blind, Placebo-Controlled Study | Not specified | Proprietary formulation (ADAPT-232) | Single dose | Positive effects on cognitive functions | Not specified | [[5](https://www.mskcc.org/cancer-care/integrative-medicine/herbs/schisandra)] |
| Nonalcoholic Steatohepatitis (NASH) | D | Randomized Controlled Trial | 56 | Powder (100 mg/kg/day) | 56 days | Alleviation of NASH in rats | Not specified | [[66](https://journals.athmsi.org/index.php/ajtcam/article/download/2211/1726/6576)] |

**Hepatoprotection** stands as the most robustly supported indication for *Schisandra chinensis*. The evidence base is built upon a foundation of high-quality systematic reviews and meta-analyses of randomized controlled trials (RCTs). One such review analyzed 29 RCTs involving 2,766 patients with chronic hepatitis B and found that adding *Schisandrae Fructus* (SF) to standard antiviral therapy resulted in statistically significant reductions in serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels compared to placebo or standard therapy alone [[63](https://journals.lww.com/stcm/fulltext/2025/03000/effects_of_schisandrae_fructus_alone_or_in.8.aspx)]. Another meta-analysis of 54 animal studies reinforces these findings, showing substantial reductions in ALT (SMD = -5.10) and AST (SMD = -4.74) [[10](https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1627081/full), [61](https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1627081/pdf)]. These preclinical and clinical findings are mechanistically sound, aligning with the herb's demonstrated ability to enhance hepatic antioxidant defenses and stimulate hepatocyte regeneration [[7](https://cmjournal.biomedcentral.com/articles/10.1186/s13020-025-01096-z), [41](https://www.sciencedirect.com/topics/medicine-and-dentistry/gomisin-a)]. The clinical derivatives bifendate (DDB) and bicyclol, which are based on schisandrin, have been widely used in China for liver protection, lending further credence to its established therapeutic role [[7](https://cmjournal.biomedcentral.com/articles/10.1186/s13020-025-01096-z), [10](https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1627081/full)].

Evidence for its **adaptogenic effects**, specifically concerning muscle strength, is growing and supported by two separate, high-quality RCTs. In a study of 45 healthy post-menopausal women, supplementation with 1000 mg/day of *Schisandra chinensis* extract for 12 weeks, combined with low-intensity exercise, led to a statistically significant increase in quadriceps muscle strength compared to placebo (p < 0.001) [[8](https://pmc.ncbi.nlm.nih.gov/articles/PMC7177795/), [56](https://www.mdpi.com/1660-4601/17/7/2475)]. A second RCT involving 54 adults over 50 years old yielded similar results, demonstrating significantly greater increases in right and left knee extensor strength with the same daily dose of extract [[50](https://www.sciencedirect.com/science/article/pii/S0002916522007237)]. Interestingly, neither study found a significant increase in appendicular skeletal muscle mass, suggesting the primary benefit is related to neuromuscular function, work capacity, or energy metabolism rather than hypertrophy [[8](https://pmc.ncbi.nlm.nih.gov/articles/PMC7177795/), [50](https://www.sciencedirect.com/science/article/pii/S0002916522007237)]. Supporting this, one of the studies noted a significant decrease in resting lactate levels after 12 weeks of supplementation, pointing towards improved metabolic efficiency [[8](https://pmc.ncbi.nlm.nih.gov/articles/PMC7177795/), [47](https://drruscio.com/schisandra-benefits/)].

For **menopausal symptoms**, a double-blind, placebo-controlled trial provided evidence for the efficacy of a proprietary Schisandra extract (BMO-30) [[58](https://pubmed.ncbi.nlm.nih.gov/27763802/), [60](https://www.researchgate.net/publication/309342787_A_randomized_double-blind_placebo-controlled_trial_of_Schisandra_chinensis_for_menopausal_symptoms)]. In this study of 36 women aged 40-70, the Schisandra group showed a significantly greater reduction in total Kupperman Index scores compared to placebo over a 6-week period (p = 0.042) [[58](https://pubmed.ncbi.nlm.nih.gov/27763802/)]. Secondary analyses revealed significant improvements in vasomotor symptoms, including hot flushes (p=0.018), sweating (p=0.009), and heart palpitations (p=0.015) [[18](https://www.drugs.com/npp/schisandra.html)]. This provides a solid rationale for its use as a complementary therapy for alleviating these common and often distressing symptoms.

Evidence for **hyperglycemia** is currently limited to a single RCT [[9](https://www.mdpi.com/2072-6643/14/15/3159)]. In this 12-week trial, participants with prediabetes who consumed a daily supplement containing 500 mg of an Omija (Schisandra) and soybean mixture experienced a significant reduction in fasting plasma glucose (-5.62 mg/dL) compared to the placebo group (+0.66 mg/dL) [[9](https://www.mdpi.com/2072-6643/14/15/3159)]. The intervention also led to a significant improvement in insulin sensitivity, as measured by the Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) [[9](https://www.mdpi.com/2072-6643/14/15/3159)]. While promising, the lack of a significant effect on HbA1c suggests that longer-term studies are needed to confirm its efficacy in glycemic control.

Other indications, such as cognitive enhancement and nonalcoholic steatohepatitis (NASH), are supported by weaker evidence. A proprietary formulation containing Schisandra improved cognitive task performance in healthy subjects in a small study [[5](https://www.mskcc.org/cancer-care/integrative-medicine/herbs/schisandra)]. In animal models, Schisandra has shown promise in mitigating NASH, but a single RCT in humans found that 100 mg/kg/day of a Schisandra powder did not achieve statistical significance in improving NASH histology compared to rosiglitazone, although it did show some beneficial effects on lipid profiles [[65](https://pubmed.ncbi.nlm.nih.gov/20427778/), [66](https://journals.athmsi.org/index.php/ajtcam/article/download/2211/1726/6576)].

#### Bottom Line
The human clinical evidence for *Schisandra chinensis* is strongest for hepatoprotection, where multiple meta-analyses of RCTs confirm its ability to reduce liver enzyme levels. Evidence for its adaptogenic effects on muscle strength in older adults is also Grade B, supported by two positive RCTs. Its efficacy in managing menopausal symptoms is supported by a Grade B RCT. Evidence for metabolic benefits in prediabetes is promising but preliminary (Grade C), requiring larger trials. For other indications like cognitive function and NASH, the evidence remains largely preclinical or from single, small studies, warranting further investigation.

---

## Dosing & Administration Protocols

Determining the appropriate dosage for *Schisandra chinensis* is a critical aspect of its clinical application, as efficacy and safety are closely tied to the concentration of bioactive lignans present in the preparation. Dosage recommendations vary widely depending on the form of the product (e.g., powdered berries, extracts, standardized capsules), the intended indication, and the specific lignan content of the batch. Standardization of the final product, typically based on the concentration of key lignans like schisandrin, is the most reliable method for ensuring consistent dosing and therapeutic outcomes.

Traditional Chinese medicine practices recommend decocting 3–9 grams of dried berries [[7](https://cmjournal.biomedcentral.com/articles/10.1186/s13020-025-01096-z), [10](https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1627081/full)]. In alternative medicine settings, powdered fruit is often administered at doses of 0.5–1.5 grams twice daily before meals for 20–30 days [[1](https://pmc.ncbi.nlm.nih.gov/articles/PMC8073495/), [18](https://www.drugs.com/npp/schisandra.html)]. Russian preparations have historically used tinctures (20-30 drops twice daily) or seed powders (0.5-1.5 g twice daily) [[18](https://www.drugs.com/npp/schisandra.html)]. However, these traditional doses lack the standardization necessary for precise clinical application.

Modern clinical trials rely on standardized extracts, which allows for more accurate dose-response analysis. For the purpose of enhancing muscle strength, a dose of 1 gram per day of *Schisandra chinensis* extract has been successfully used in two separate randomized, double-blind, placebo-controlled trials [[8](https://pmc.ncbi.nlm.nih.gov/articles/PMC7177795/), [47](https://drruscio.com/schisandra-benefits/), [50](https://www.sciencedirect.com/science/article/pii/S0002916522007237)]. In one study, this was delivered as two 250 mg pills taken twice daily after meals [[8](https://pmc.ncbi.nlm.nih.gov/articles/PMC7177795/)]. Another trial used 392 mg of extract taken twice daily for 12 weeks to address menopausal symptoms [[18](https://www.drugs.com/npp/schisandra.html)]. For individuals seeking to improve athletic performance, a proprietary formulation contained tablets with 91.1 mg of extract per tablet, standardized for schizandrin and gamma-schizandrin [[18](https://www.drugs.com/npp/schisandra.html)].

The following table summarizes available dosing information, highlighting the importance of lignan standardization. It is crucial to note that many commercially available products may not be accurately labeled, and the actual lignan content can vary significantly based on the geographical origin of the plant and the processing method used [[26](https://pubmed.ncbi.nlm.nih.gov/21355273/), [31](https://www.researchgate.net/publication/287369526_Quality_Analysis_of_Raw_and_Processed_Schisandra_Chinensis_Fructus_by_Simultaneous_Determination_of_Eleven_Bioactive_Lignans_Using_RP-HPLC_Method)].

| Form | Adult Dose (per dose) | Daily Range | Frequency | Timing | Standardization (% marker) | Equivalency | Clinical Context | Sources (PMIDs) |
| :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- |
| **Powdered Fruit** | 0.5–1.5 g | 1.0–3.0 g | Twice daily | Before meals | Not applicable | Not specified | Traditional use, adaptogens | [[1](https://pmc.ncbi.nlm.nih.gov/articles/PMC8073495/), [18](https://www.drugs.com/npp/schisandra.html)] |
| **Extract (Capsules)** | 250 mg | 1000 mg | Twice daily | After breakfast & dinner | 4.92 ± 0.06 mg/g schizandrin | 1000 mg/day | Muscle strength in older adults | [[8](https://pmc.ncbi.nlm.nih.gov/articles/PMC7177795/), [56](https://www.mdpi.com/1660-4601/17/7/2475)] |
| **Extract (Capsules)** | 392 mg | 784 mg | Twice daily | Not specified | Not specified | Not specified | Menopausal symptoms | [[18](https://www.drugs.com/npp/schisandra.html)] |
| **Tablets** | 91.1 mg | Not specified | Not specified | Not specified | Standardized for schizandrin & gamma-schizandrin | Not specified | Athletic performance | [[18](https://www.drugs.com/npp/schisandra.html)] |
| **Liquid Extract (Tincture)** | 20–30 drops | Not specified | Twice daily | Not specified | Not specified | Not specified | Traditional use (Russia) | [[18](https://www.drugs.com/npp/schisandra.html)] |
| **Powder (Seed)** | 0.5–1.5 g | Not specified | Not specified | Not specified | Not specified | Not specified | Traditional use (Russia) | [[18](https://www.drugs.com/npp/schisandra.html)] |
| **Ethanol Extract** | 20 mg lignans | Not specified | Not specified | Not specified | 20 mg lignans (equivalent to 1.5 g fruit) | 1.5 g fruit | Liver function in hepatitis | [[44](https://onlinelibrary.wiley.com/doi/10.1155/2016/3530971)] |

The timing of administration can also influence outcomes. For example, in Russia, preparations are often taken before meals [[1](https://pmc.ncbi.nlm.nih.gov/articles/PMC8073495/), [18](https://www.drugs.com/npp/schisandra.html)]. In the muscle strength studies, the extract was taken after breakfast and dinner to ensure consistent plasma levels throughout the day [[8](https://pmc.ncbi.nlm.nih.gov/articles/PMC7177795/)]. The duration of treatment is another key variable. Benefits for muscle strength and menopausal symptoms were typically observed after 12 weeks of continuous use [[8](https://pmc.ncbi.nlm.nih.gov/articles/PMC7177795/), [18](https://www.drugs.com/npp/schisandra.html)]. For liver conditions, treatment durations in clinical trials ranged from 4 weeks to over 7 months, depending on the specific pathology and concomitant therapies [[44](https://onlinelibrary.wiley.com/doi/10.1155/2016/3530971), [63](https://journals.lww.com/stcm/fulltext/2025/03000/effects_of_schisandrae_fructus_alone_or_in.8.aspx)].

It is important to recognize that optimal dosing is not yet fully established and may depend on individual factors and the specific condition being treated [[47](https://drruscio.com/schisandra-benefits/)]. While most studies report good tolerability at recommended doses, exceeding these amounts may increase the risk of adverse effects, such as restlessness or insomnia [[1](https://pmc.ncbi.nlm.nih.gov/articles/PMC8073495/), [55](https://www.sciencedirect.com/topics/medicine-and-dentistry/schisandra)]. Therefore, clinicians should advise patients to adhere strictly to product labeling or professional guidance, starting with the lowest effective dose and titrating upwards if necessary, while monitoring for any adverse reactions.

#### Bottom Line
Standardized extracts of *Schisandra chinensis* are the preferred form for clinical use due to their consistent lignan content. Effective doses for muscle strength in older adults have been established at 1000 mg/day, while 784 mg/day has been used for menopausal symptoms. The most reliable way to determine dosage is to look for products standardized for specific lignans like schisandrin. Clinicians should counsel patients on adherence to recommended dosages and treatment durations, which are typically 12 weeks for neuromuscular and menopausal benefits.

---

## Safety Profile & Toxicology

The overall safety profile of *Schisandra chinensis* appears favorable when used at recommended therapeutic doses, with no serious adverse effects reported in most clinical trials [[5](https://www.mskcc.org/cancer-care/integrative-medicine/herbs/schisandra), [10](https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1627081/full)]. Minor side effects such as sleepiness, cold extremities, mild digestive upset, or allergic reactions like hives have been reported in some studies but occurred with similar frequency in placebo groups, making causality uncertain [[5](https://www.mskcc.org/cancer-care/integrative-medicine/herbs/schisandra), [47](https://drruscio.com/schisandra-benefits/)]. Overdose may cause dyspnea, restlessness, or insomnia [[1](https://pmc.ncbi.nlm.nih.gov/articles/PMC8073495/), [55](https://www.sciencedirect.com/topics/medicine-and-dentistry/schisandra)]. However, the potential for severe, life-threatening drug-herb interactions and specific idiosyncratic adverse events necessitates a cautious approach to its use.

The most significant safety concern is the potent inhibition of cytochrome P450 enzymes (particularly CYP3A4) and P-glycoprotein, which can lead to clinically significant interactions with a vast number of commonly prescribed medications [[5](https://www.mskcc.org/cancer-care/integrative-medicine/herbs/schisandra), [18](https://www.drugs.com/npp/schisandra.html)]. As previously detailed, this inhibition can dramatically increase the plasma concentrations of co-administered drugs, leading to toxicity. High-risk drug classes include immunosuppressants (tacrolimus, cyclosporine A), calcium channel blockers (verapamil, diltiazem), statins (simvastatin, lovastatin), benzodiazepines (midazolam), and many others metabolized by CYP3A4 [[2](https://www.webmd.com/vitamins/ai/ingredientmono-376/schisandra), [5](https://www.mskcc.org/cancer-care/integrative-medicine/herbs/schisandra), [35](https://pmc.ncbi.nlm.nih.gov/articles/PMC2686071/)]. Even anticoagulants and diabetes medications are implicated, though the clinical relevance requires further study [[5](https://www.mskcc.org/cancer-care/integrative-medicine/herbs/schisandra), [47](https://drruscio.com/schisandra-benefits/)]. This interaction potential is so profound that concurrent use with narrow-therapeutic-index drugs is generally contraindicated.

Beyond pharmacokinetic interactions, there is documented evidence of severe, direct adverse events. A case report described a patient who developed a severe intracranial hemorrhage (subarachnoid haemorrhage) and thrombocytopenia following the initiation of a multi-component tablet containing *Schisandra chinensis* [[3](https://link.springer.com/article/10.1007/s40278-025-90761-y), [4](https://pubmed.ncbi.nlm.nih.gov/41021848)]. While definitive proof of causality is impossible in a single case, the temporal association and the known mechanism of CYP3A4 inhibition disrupting coagulation pathways make this a serious and alarming possibility that cannot be ignored [[4](https://pubmed.ncbi.nlm.nih.gov/41021848)]. This event underscores the need for extreme caution in patients with bleeding disorders or those on anticoagulant therapy.

Allergic reactions represent another important safety consideration. Shengmai injection, a traditional Chinese medicine formula containing *Schisandra chinensis*, was associated with 179 reported cases of severe adverse reactions, including 90 cases of anaphylactic shock, accounting for about 35.2% of all severe reactions reported for TCM injections in one database analysis [[53](https://bmcmedinformdecismak.biomedcentral.com/articles/10.1186/s12911-018-0599-5)]. The most common adverse reaction categories included general disorders, respiratory system disorders, and cardiovascular disorders [[53](https://bmcmedinformdecismak.biomedcentral.com/articles/10.1186/s12911-018-0599-5)]. This highlights the risk of hypersensitivity, particularly with injectable formulations, and the importance of screening for allergies before administration.

Contraindications for *Schisandra chinensis* are outlined in traditional sources and should be respected. It is considered contraindicated in cases of "excess heat" or acute infections, as it may exacerbate symptoms [[55](https://www.sciencedirect.com/topics/medicine-and-dentistry/schisandra)]. It is also not recommended for patients with high gastric acidity, peptic ulcers, epilepsy, hypertension, or elevated intracranial pressure [[55](https://www.sciencedirect.com/topics/medicine-and-dentistry/schisandra)]. Due to its potential to increase uterine contractility, it is not advised for use during pregnancy [[55](https://www.sciencedirect.com/topics/medicine-and-dentistry/schisandra)]. Long-term safety data beyond several months of use is lacking due to a scarcity of extended human studies [[47](https://drruscio.com/schisandra-benefits/)].

The following table provides a summary of the known adverse events and safety concerns associated with *Schisandra chinensis*.

| AE/Concern | Frequency/Severity | Mechanism/Risk Factors | Management | Evidence (PMIDs) |
| :--- | :--- | :--- | :--- | :--- |
| **Drug-Herb Interactions** | High Risk | Potent inhibition of CYP3A4 and P-glycoprotein, leading to increased drug exposure and toxicity. | Screen for concurrent medications metabolized by CYP3A4/P-gp. Avoid concurrent use with narrow-therapeutic-index drugs. Adjust drug doses if co-administration is unavoidable. | [[2](https://www.webmd.com/vitamins/ai/ingredientmono-376/schisandra), [5](https://www.mskcc.org/cancer-care/integrative-medicine/herbs/schisandra), [18](https://www.drugs.com/npp/schisandra.html), [35](https://pmc.ncbi.nlm.nih.gov/articles/PMC2686071/)] |
| **Intracranial Hemorrhage** | Rare, Severe | Potential for causing a hemorrhagic diathesis, possibly via CYP3A4 inhibition affecting coagulation pathways. | Discontinue use immediately. Seek immediate medical attention for any signs of bleeding or neurological symptoms. | [[3](https://link.springer.com/article/10.1007/s40278-025-90761-y), [4](https://pubmed.ncbi.nlm.nih.gov/41021848)] |
| **Anaphylaxis / Allergic Reactions** | Rare | Hypersensitivity to herbal components. Risk higher with injectable preparations. | Discontinue use. Treat with standard protocols for anaphylaxis (e.g., epinephrine). Monitor for rash, hives, itching. | [[47](https://drruscio.com/schisandra-benefits/), [53](https://bmcmedinformdecismak.biomedcentral.com/articles/10.1186/s12911-018-0599-5)] |
| **Restlessness / Insomnia** | Mild, Common | CNS stimulation at higher doses. | Reduce dose or discontinue use. | [[1](https://pmc.ncbi.nlm.nih.gov/articles/PMC8073495/), [55](https://www.sciencedirect.com/topics/medicine-and-dentistry/schisandra)] |
| **Gastrointestinal Upset** | Mild, Possible | Not specified. | Discontinue use. Symptomatic management. | [[47](https://drruscio.com/schisandra-benefits/)] |
| **Contraindicated Conditions** | Absolute Contraindication | Theoretical risk of exacerbating conditions of excess heat, high gastric acid, or hypertension. | Do not prescribe in patients with active peptic ulcer disease, uncontrolled hypertension, epilepsy, or during pregnancy. | [[55](https://www.sciencedirect.com/topics/medicine-and-dentistry/schisandra)] |

In conclusion, while *Schisandra chinensis* is generally well-tolerated, its safety profile is defined by a high potential for severe drug interactions. The risk of idiosyncratic events like intracranial hemorrhage, though rare, demands vigilance. Clinicians must conduct thorough medication histories and screen for contraindications before recommending this herb, prioritizing patient safety above all else.

---

## Quality Control & Adulteration

Ensuring the quality, purity, and authenticity of *Schisandra chinensis* products is a critical challenge in herbal medicine, as adulteration can compromise both efficacy and safety. The primary issue stems from the frequent substitution of *Schisandra chinensis* (North Wu wei zi) with *Schisandra sphenanthera* (South Nanwuwei zi) in the market [[30](https://www.sciencedirect.com/science/article/abs/pii/S073170851630485X), [32](https://www.researchgate.net/publication/395895340_Identification_of_Schisandra_chinensis_Seeds_and_Exclusion_of_Common_Adulterants_by_Allele-Specific_PCR_Based_on_ITS2_Sequences)]. While both species are used medicinally, they differ in their chemical composition and clinical effects, with *S. sphenanthera* being less potent in certain systems [[30](https://www.sciencedirect.com/science/article/abs/pii/S073170851630485X)]. Rigorous analytical methods are therefore essential for authentication and quality control.

The Chinese Pharmacopoeia provides official standards for quality control indicators for both species [[30](https://www.sciencedirect.com/science/article/abs/pii/S073170851630485X)]. For *Schisandra chinensis* (Wuweizi), the markers are schisandrin and deoxyschisandrin, whereas for *Schisandra sphenanthera* (Nan-wuweizi), the markers are schisantherin A and anwulignan [[30](https://www.sciencedirect.com/science/article/abs/pii/S073170851630485X)]. Simple thin-layer chromatography (TLC) and high-performance liquid chromatography (HPLC) methods have been developed to differentiate the two species and detect adulteration in crude drugs and finished products [[30](https://www.sciencedirect.com/science/article/abs/pii/S073170851630485X), [32](https://www.researchgate.net/publication/395895340_Identification_of_Schisandra_chinensis_Seeds_and_Exclusion_of_Common_Adulterants_by_Allele-Specific_PCR_Based_on_ITS2_Sequences)]. These methods can reliably identify the presence of the respective marker compounds and detect as little as 5% adulteration of *S. sphenanthera* in *S. chinensis* [[30](https://www.sciencedirect.com/science/article/abs/pii/S073170851630485X)]. Statistical models based on the HPLC peak area ratio of anwulignan/schisandrin have been created to quantify the extent of adulteration in mixtures [[30](https://www.sciencedirect.com/science/article/abs/pii/S073170851630485X), [32](https://www.researchgate.net/publication/395895340_Identification_of_Schisandra_chinensis_Seeds_and_Exclusion_of_Common_Adulterants_by_Allele-Specific_PCR_Based_on_ITS2_Sequences)].

Using these methods, several studies have uncovered significant instances of adulteration in commercial products. An analysis of 36 different Chinese patent medicines revealed that two products, Renshen Wuweizi Granules and Fenghan Kesou Pills, were completely substituted with *S. sphenanthera* instead of the prescribed *S. chinensis*, representing a violation of statutory prescriptions [[30](https://www.sciencedirect.com/science/article/abs/pii/S073170851630485X), [32](https://www.researchgate.net/publication/395895340_Identification_of_Schisandra_chinensis_Seeds_and_Exclusion_of_Common_Adulterants_by_Allele-Specific_PCR_Based_on_ITS2_Sequences)]. Further analysis of 27 batches of crude drugs labeled as Wuweizi found that eight were adulterated with Nanwuwei zi [[32](https://www.researchgate.net/publication/395895340_Identification_of_Schisandra_chinensis_Seeds_and_Exclusion_of_Common_Adulterants_by_Allele-Specific_PCR_Based_on_ITS2_Sequences)]. These findings highlight the necessity of third-party testing for authentic products.

Beyond species-level adulteration, the internal quality of *Schisandra chinensis* can vary significantly based on geographical origin, cultivation practices, and processing methods. A study evaluating samples from 10 different producing sites in northeast China found variability in appearance, water-soluble extractives, ash content, and, most importantly, the concentration of major active lignans [[26](https://pubmed.ncbi.nlm.nih.gov/21355273/)]. This regional variation underscores the need for comprehensive quality standards that go beyond simple identity tests to assess potency. Advanced analytical techniques like ultra-performance liquid chromatography (UPLC) and ultra-performance liquid chromatography-quadrupole-time-of-flight mass spectrometry (UPLC-Q/TOF-MS) are now used for detailed chemical profiling and quality assessment [[6](https://www.scientificarchives.com/article/schisandra-chinensis-in-liver-disease-exploring-the-mechanisms-and-therapeutic-promise-of-an-ancient-chinese-botanical), [31](https://www.researchgate.net/publication/287369526_Quality_Analysis_of_Raw_and_Processed_Schisandra_Chinensis_Fructus_by_Simultaneous_Determination_of_Eleven_Bioactive_Lignans_Using_RP-HPLC_Method)].

To address these challenges, the concept of Quality Markers (Q-markers) has been proposed. Q-markers are biochemically active compounds that are quantifiable and correlate with the traditional therapeutic effects of the herb. Based on network pharmacology and in vitro validation, six compounds—schisandrol A, angeloylgomisin H, schisantherin A, schisantherin B, schisandrin A, and schisandrin C—have been identified as potential Q-markers for *Schisandra chinensis* due to their roles in hepatoprotection and other key activities [[27](https://www.mdpi.com/2297-8739/11/3/88)]. Developing validated HPLC or UPLC methods for the simultaneous quantification of these Q-markers provides a robust framework for quality control, ensuring that a product contains sufficient levels of the key bioactive components to be therapeutically effective [[27](https://www.mdpi.com/2297-8739/11/3/88)].

The United States Pharmacopeia (USP) provides reference standards for *Schisandra chinensis Fruit Dry Extract* and schisandrin, which are invaluable tools for laboratories performing quality control and analytical testing [[25](https://store.usp.org/product/1609909?srsltid=AfmBOoqNqG1x6BTOgyU9rBS5P1Z8PV-eYwq306iCf7CvoAtYii6FbRus), [29](https://www.sigmaaldrich.com/US/en/product/usp/1609909?srsltid=AfmBOoqJ0MLKK1F625FJhxMygiLvsebpvq4eJubwjuPp3WfCyJNOK75q)]. These certified reference materials allow for the accurate identification and quantification of the herb and its key constituents, ensuring consistency and reliability in testing procedures [[29](https://www.sigmaaldrich.com/US/en/product/usp/1609909?srsltid=AfmBOoqJ0MLKK1F625FJhxMygiLvsebpvq4eJubwjuPp3WfCyJNOK75q)]. Using these standards helps to verify the identity, purity, and assay of commercial products, providing a layer of assurance for consumers and clinicians.

#### Bottom Line
Quality control of *Schisandra chinensis* is paramount due to the prevalence of species-level adulteration with *S. sphenanthera*. Authentication relies on analytical methods like HPLC and TLC using schisandrin and anwulignan as specific markers. Internal quality also varies geographically, necessitating the use of advanced analytical techniques like UPLC for comprehensive chemical profiling. The adoption of Quality Marker (Q-marker) principles and the use of certified reference standards from organizations like the USP are critical for ensuring the potency, consistency, and safety of *Schisandra chinensis* products.

---

## Comparative Analysis & Clinical Decision Rules

When considering the clinical use of *Schisandra chinensis*, it is essential to place it within the context of existing treatments (the standard of care) and establish clear, evidence-based decision rules for its safe and effective application. The herb's primary strength lies in its adjunctive role, particularly for liver protection, where it complements conventional therapies without replacing them. Its main advantage is a favorable safety profile at therapeutic doses and a multi-targeted mechanism of action that supports organ recovery. However, its profound potential for drug interactions presents a significant disadvantage that must be managed carefully.

In the management of chronic hepatitis B, the standard of care involves antiviral therapy with nucleos(t)ide analogues (e.g., entecavir, tenofovir) [[63](https://journals.lww.com/stcm/fulltext/2025/03000/effects_of_schisandrae_fructus_alone_or_in.8.aspx)]. A systematic review of 29 RCTs found that adding *Schisandrae Fructus* (SF) to this regimen significantly reduced serum ALT and AST levels compared to antiviral therapy alone [[63](https://journals.lww.com/stcm/fulltext/2025/03000/effects_of_schisandrae_fructus_alone_or_in.8.aspx)]. While SF did not appear to have a direct antiviral effect, its primary benefit was in mitigating the liver inflammation and damage caused by the viral infection and the subsequent treatment, thereby improving liver function [[63](https://journals.lww.com/stcm/fulltext/2025/03000/effects_of_schisandrae_fructus_alone_or_in.8.aspx)]. Compared to the standard of care, SF offers an effective and relatively safe way to manage drug-induced liver injury, a common complication of antiviral therapy. Unlike synthetic hepatoprotectants like bifendate or bicyclol, which are derived from schisandrin, SF is a natural product that may offer a broader spectrum of supportive benefits, such as reducing fatigue and improving appetite, which are common in chronic liver disease [[10](https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1627081/full), [47](https://drruscio.com/schisandra-benefits/)].

For age-related sarcopenia and decreased muscle strength, the standard of care includes resistance training and adequate protein intake. *Schisandra chinensis* does not replace exercise but has demonstrated ergogenic effects when combined with low-intensity exercise. Two RCTs showed that 1g/day of *Schisandra* extract significantly augmented the gains in knee extensor strength achieved through walking in older adults [[8](https://pmc.ncbi.nlm.nih.gov/articles/PMC7177795/), [50](https://www.sciencedirect.com/science/article/pii/S0002916522007237)]. Compared to typical exercise interventions, *Schisandra* provides an added benefit that may help overcome anabolic resistance in aging, a condition where the muscle becomes less responsive to the stimulus of exercise. It represents a safe, natural adjuvant to physical therapy programs aimed at improving mobility and functional independence in the elderly.

The following IF/THEN/BECAUSE clinical decision rules are designed to guide clinicians in navigating the complexities of prescribing *Schisandra chinensis*, prioritizing patient safety.

**IF** a patient is prescribed a narrow-therapeutic-index drug metabolized by CYP3A4 (e.g., cyclosporine, tacrolimus, sirolimus, everolimus, amiodarone, verapamil, simvastatin, lovastatin, midazolam).
**THEN** advise against the concurrent use of *Schisandra chinensis*.
**BECAUSE** potent inhibition of CYP3A4 by *Schisandra* lignans can lead to a significant increase in the plasma concentration of these drugs, resulting in a high risk of severe toxicity, organ damage, or death.

**IF** a patient is prescribed a P-glycoprotein (P-gp) substrate drug (e.g., digoxin, fexofenadine, paclitaxel, vincristine, dabigatran).
**THEN** monitor the patient closely for signs of increased drug effects or toxicity if *Schisandra chinensis* is used concurrently.
**BECAUSE** *Schisandra* inhibits P-gp, which can increase the bioavailability and systemic exposure of P-gp substrate drugs, potentially leading to adverse events.

**IF** a patient has a history of intracranial hemorrhage, bleeding disorder, or is on anticoagulant therapy (warfarin, DOACs).
**THEN** avoid prescribing *Schisandra chinensis*.
**BECAUSE** A case report links its use to a severe intracranial hemorrhage, and its inhibition of CYP3A4 may disrupt normal coagulation pathways, posing a significant bleeding risk.

**IF** a patient is experiencing menopausal symptoms, specifically hot flashes, sweating, or palpitations.
**THEN** consider recommending a standardized *Schisandra chinensis* extract as a complementary therapy.
**BECAUSE** A randomized controlled trial demonstrated that a proprietary extract was significantly more effective than placebo in reducing the severity of these vasomotor symptoms.

**IF** a patient has chronic hepatitis B or drug-induced liver injury and is undergoing standard therapy.
**THEN** discuss the potential adjunctive use of a standardized *Schisandra* preparation to support liver function.
**BECAUSE** Multiple systematic reviews and meta-analyses show that *Schisandra* can significantly reduce serum liver enzymes, indicating a protective effect on the liver.

**IF** a patient is pregnant or breastfeeding.
**THEN** do not recommend *Schisandra chinensis*.
**BECAUSE** Traditional use and pharmacological data suggest it can increase uterine contractility, making it unsafe during pregnancy. Its safety in breastfeeding has not been established.

These rules emphasize a risk-benefit analysis where the proven, multi-faceted benefits of *Schisandra* are weighed against the high certainty of its dangerous drug interaction potential. The default recommendation for most patients, especially those on polypharmacy, should be avoidance.

---

## Case Studies & Research Frontiers

Clinical practice with *Schisandra chinensis* is enriched by case studies that illustrate its real-world application and potential pitfalls, while ongoing research continues to unravel its complex biology and explore novel therapeutic avenues. These insights bridge the gap between controlled trial data and the nuanced reality of patient care.

A compelling case study involves a 64-year-old renal transplant recipient who developed drug-induced hepatitis while on tacrolimus therapy [[18](https://www.drugs.com/npp/schisandra.html)]. In China, it is common practice to co-administer *Schisandra* with tacrolimus in such situations [[18](https://www.drugs.com/npp/schisandra.html)]. The patient was started on a *Schisandra*-containing preparation, which led to a 34% reduction in his tacrolimus dosage requirement over six months, compared to only a 14.3% reduction in a control group. This allowed for more accurate dosing and fewer adjustments, ultimately saving an estimated $6.15 per patient per day [[18](https://www.drugs.com/npp/schisandra.html)]. This case highlights the dual nature of the interaction: *Schisandra*'s inhibition of CYP3A4 and P-gp increases tacrolimus bioavailability, allowing for a lower, safer maintenance dose. It serves as a powerful example of how understanding drug-herb interactions can be leveraged to optimize therapy, but it also exemplifies the necessity of close monitoring to prevent toxicity.

In contrast, a contrasting case illustrates the risks. A patient taking a multi-component tablet containing *Schisandra chinensis* developed spontaneous subdural and subarachnoid hemorrhage and de novo immune thrombocytopenia [[4](https://pubmed.ncbi.nlm.nih.gov/41021848)]. Although establishing a direct causal link is challenging, the temporal sequence and the known mechanism of CYP3A4 inhibition disrupting coagulation pathways make this a plausible adverse event [[4](https://pubmed.ncbi.nlm.nih.gov/41021848)]. This case serves as a stark reminder of the potential for idiosyncratic, severe adverse reactions and the importance of thoroughly screening patients for bleeding risks and anticoagulant use before prescribing *Schisandra*.

Looking forward, several research frontiers hold significant promise for expanding the clinical utility of *Schisandra chinensis*.

First, **modulating the gut-liver axis** is an emerging area of intense interest. Preclinical studies show that *Schisandra* lignans mitigate non-alcoholic steatohepatitis (NASH) in mice by restoring gut microbiota balance, improving colon barrier integrity, and activating the Farnesoid X receptor (FXR) in the gut-liver axis [[43](https://www.sciencedirect.com/science/article/abs/pii/S0378874125004854)]. This FXR activation improves bile acid homeostasis and reduces hepatic inflammation [[43](https://www.sciencedirect.com/science/article/abs/pii/S0378874125004854)]. Future research will focus on confirming these effects in human trials and exploring whether specific lignan fractions can be optimized to target this axis for the treatment of metabolic liver diseases like NASH, a condition with a projected global prevalence increase of 48% between 2016 and 2030 [[43](https://www.sciencedirect.com/science/article/abs/pii/S0378874125004854)].

Second, **enhancing bioavailability and targeted delivery** is a key challenge. Due to the poor water sololubility and extensive first-pass metabolism of its lignans, achieving therapeutic concentrations in target tissues is difficult [[7](https://cmjournal.biomedcentral.com/articles/10.1186/s13020-025-01096-z)]. Research is underway to develop advanced delivery systems such as nanoparticles, liposomes, phytosomes, and self-emulsifying drug delivery systems (SEDDS) [[7](https://cmjournal.biomedcentral.com/articles/10.1186/s13020-025-01096-z)]. Phytosomes, in particular, offer advantages by forming molecular complexes with phospholipids that enhance aqueous solubility, improve intestinal absorption, and provide sustained release, potentially overcoming the limitations of traditional extracts [[7](https://cmjournal.biomedcentral.com/articles/10.1186/s13020-025-01096-z)]. Successful development of these systems could unlock the therapeutic potential of *Schisandra* at much lower doses, reducing the risk of interactions.

Third, **exploring synergistic herbal pairings** is a promising avenue. A rat model of Alzheimer's disease demonstrated that a combination of *Schisandra chinensis* and *Evodia rutaecarpa* was more effective at improving cognitive function and reducing pathological markers (amyloid plaques and tau tangles) than either herb alone [[22](https://www.sciencedirect.com/science/article/pii/S2405844023091508), [24](https://www.cell.com/heliyon/fulltext/S2405-8440(23)09150-8)]. The combination worked synergistically by targeting different pathological pathways simultaneously: *Schisandra* reduced Aβ production while *Evodia* reduced P-tau expression [[24](https://www.cell.com/heliyon/fulltext/S2405-8440(23)09150-8)]. Furthermore, *Evodia* may enhance the brain delivery of *Schisandra* lignans by increasing blood-brain barrier permeability, addressing a key limitation of the herb [[24](https://www.cell.com/heliyon/fulltext/S2405-8440(23)09150-8)]. This points to the potential for developing highly effective, multi-herb formulations that leverage synergistic interactions for complex conditions like neurodegenerative diseases.

Finally, **large-scale, long-term human trials** are critically needed to fill existing evidence gaps. While the current evidence is promising, there is a lack of large RCTs assessing histological changes in liver disease, dose-response relationships for various indications, and long-term safety data beyond several months of use [[45](https://www.researchgate.net/publication/380447294_Schisandra_chinensis_in_Liver_Disease_Exploring_the_Mechanisms_and_Therapeutic_Promise_of_an_Ancient_Chinese_Botanical), [47](https://drruscio.com/schisandra-benefits/)]. Future research should prioritize head-to-head comparisons with standard therapies for conditions like NASH and hepatitis, as well as investigations into its effects on mood, stress resilience, and cardiovascular health, which are supported by preclinical data but remain understudied in humans [[6](https://www.scientificarchives.com/article/schisandra-chinensis-in-liver-disease-exploring-the-mechanisms-and-therapeutic-promise-of-an-ancient-chinese-botanical), [47](https://drruscio.com/schisandra-benefits/)].

#### Bottom Line
Case studies reveal the dual-edged nature of *Schisandra chinensis*, offering both therapeutic benefits when used strategically (as in transplant patients) and posing significant risks (as in cases of intracranial hemorrhage). The future of *Schisandra* research is focused on leveraging its unique mechanisms, such as gut-liver axis modulation, and overcoming its pharmacokinetic limitations through advanced delivery systems. Synergistic herbal combinations and large-scale human trials are essential next steps to validate its efficacy, expand its therapeutic applications, and firmly establish its place in evidence-based medicine.

---

## Red Flags & Triage Parameters

Given the potent pharmacological activity and significant drug interaction potential of *Schisandra chinensis*, clinicians must employ a structured triage process to identify patients at high risk before initiating therapy. The following red flags and corresponding triage parameters serve as a clinical checklist to ensure patient safety.

**Red Flag 1: Polypharmacy, Especially with Narrow-Therapeutic-Index Drugs**
*   **Description:** Patients taking multiple medications, particularly those with a narrow therapeutic index, are at highest risk. This category includes many cardiovascular drugs, immunosuppressants, and psychiatric medications.
*   **Triage Parameter:** Conduct a thorough medication reconciliation. Specifically identify any drugs that are known substrates of CYP3A4 or P-glycoprotein. This includes, but is not limited to:
    *   **Immunosuppressants:** Tacrolimus, cyclosporine A, sirolimus, everolimus.
    *   **Calcium Channel Blockers:** Verapamil, diltiazem.
    *   **Statins:** Simvastatin, lovastatin.
    *   **Benzodiazepines:** Midazolam, triazolam.
    *   **Antiarrhythmics:** Amiodarone.
    *   **Antifungals:** Ketoconazole, itraconazole.
    *   **Antipsychotics:** Quetiapine, aripiprazole.
    *   **Chemotherapy Agents:** Paclitaxel, docetaxel.
    *   **Anticoagulants:** Warfarin (metabolized by multiple CYPs).
*   **Action:** If a patient is taking any of these medications, strongly advise against the concurrent use of *Schisandra chinensis*. The risk of severe toxicity far outweighs the potential benefits. If the patient insists on using it, close monitoring of drug levels and clinical signs of toxicity is mandatory.

**Red Flag 2: History of Bleeding Disorders or Active Bleeding**
*   **Description:** A case report of a patient developing a severe intracranial hemorrhage while taking a multi-component tablet containing *Schisandra* raises a serious safety concern [[3](https://link.springer.com/article/10.1007/s40278-025-90761-y), [4](https://pubmed.ncbi.nlm.nih.gov/41021848)].
*   **Triage Parameter:** Ask specifically about a personal or family history of bleeding disorders, stroke, aneurysms, or clotting issues. Also, inquire about recent surgeries or trauma.
*   **Action:** Do not prescribe *Schisandra chinensis* to patients with a known bleeding diathesis. Exercise extreme caution in patients with a history of hypertension or cerebrovascular disease, as the risk of hemorrhage may be elevated.

**Red Flag 3: Use of Anticoagulant or Antiplatelet Therapy**
*   **Description:** Given the potential for a hemorrhagic diathesis, patients on blood thinners are at increased risk.
*   **Triage Parameter:** Identify all patients on warfarin, direct oral anticoagulants (DOACs), aspirin, clopidogrel, or other antiplatelet agents.
*   **Action:** Advise against concurrent use. The theoretical risk of potentiating anticoagulation or inducing a hemorrhagic event is too high. If co-administration is deemed absolutely necessary after a thorough risk-benefit discussion, very close monitoring of INR or platelet function is required.

**Red Flag 4: Pregnancy or Breastfeeding**
*   **Description:** Traditional use and pharmacological data indicate that *Schisandra* can increase uterine contractility.
*   **Triage Parameter:** Routinely screen female patients of childbearing potential for pregnancy status.
*   **Action:** Contraindicated in pregnancy. There is insufficient safety data for use during breastfeeding. Advise patients to discontinue use if they become pregnant or are planning to become pregnant.

**Red Flag 5: Uncontrolled Hypertension or Epilepsy**
*   **Description:** Traditional Chinese Medicine texts list these conditions as contraindications [[55](https://www.sciencedirect.com/topics/medicine-and-dentistry/schisandra)].
*   **Triage Parameter:** Assess blood pressure and review the patient's neurological history.
*   **Action:** Avoid prescribing *Schisandra chinensis* to patients with uncontrolled hypertension or active epilepsy. Its CNS-stimulating effects could theoretically exacerbate seizures or raise blood pressure [[55](https://www.sciencedirect.com/topics/medicine-and-dentistry/schisandra)].

**Red Flag 6: Known Allergy to Herbs in the Schisandraceae Family**
*   **Description:** While rare, allergic reactions, including anaphylaxis, have been reported, particularly with injectable formulations [[53](https://bmcmedinformdecismak.biomedcentral.com/articles/10.1186/s12911-018-0599-5)].
*   **Triage Parameter:** Ask about any history of herbal allergies or unusual reactions to dietary supplements.
*   **Action:** Proceed with caution and start with a very low dose. Counsel the patient to discontinue use and seek immediate medical attention if any signs of an allergic reaction occur.

By systematically applying these triage parameters, clinicians can effectively mitigate the risks associated with *Schisandra chinensis* and ensure that its therapeutic benefits are safely realized in suitable patient populations.

---

## Quality & Adulteration Checklist

Ensuring the quality and authenticity of *Schisandra chinensis* products is a shared responsibility among manufacturers, regulators, and healthcare providers. Clinicians should be aware of key quality attributes and potential adulterants to make informed recommendations to their patients. This checklist provides a framework for evaluating the quality of a *Schisandra chinensis* product.

| Category | Attribute/Marker | Method | Threshold/Range | Adulterant(s) | Detection Risk | Sources (PMIDs) |
| :--- | :--- | :--- | :--- | :--- | :--- | :--- |
| **Identity** | Species Authentication | Thin-Layer Chromatography (TLC) | Presence of schisandrin (for *S. chinensis*) and absence of anwulignan. | *Schisandra sphenanthera* | High | [[30](https://www.sciencedirect.com/science/article/abs/pii/S073170851630485X), [32](https://www.researchgate.net/publication/395895340_Identification_of_Schisandra_chinensis_Seeds_and_Exclusion_of_Common_Adulterants_by_Allele-Specific_PCR_Based_on_ITS2_Sequences)] |
| **Identity** | Species Authentication | Allele-Specific PCR (DNA Barcoding) | Amplification of a specific ITS2 gene band for *S. chinensis*. | *S. sphenanthera* | High | [[32](https://www.researchgate.net/publication/395895340_Identification_of_Schisandra_chinensis_Seeds_and_Exclusion_of_Common_Adulterants_by_Allele-Specific_PCR_Based_on_ITS2_Sequences)] |
| **Potency** | Total Lignans | HPLC | >7.2% (as deoxyschizandrin equivalent) | Dilution with inert fillers | Moderate | [[19](https://www.sciencedirect.com/science/article/pii/S0090955624053819)] |
| **Potency** | Individual Lignans (Q-markers) | UPLC, HPLC | Varies by compound; e.g., schisandrol A is often most abundant. | Substitution with lower-potency species | High | [[27](https://www.mdpi.com/2297-8739/11/3/88), [31](https://www.researchgate.net/publication/287369526_Quality_Analysis_of_Raw_and_Processed_Schisandra_Chinensis_Fructus_by_Simultaneous_Determination_of_Eleven_Bioactive_Lignans_Using_RP-HPLC_Method)] |
| **Potency** | Schisandrin Content | HPLC | >0.40% (in raw material) | Dilution with inert fillers | Moderate | [[26](https://pubmed.ncbi.nlm.nih.gov/21355273/)] |
| **Purity** | Water-Soluble Extractive | Gravimetric | >45.0% | Dilution with water-insoluble fillers | Low | [[26](https://pubmed.ncbi.nlm.nih.gov/21355273/)] |
| **Purity** | Ash Content | Gravimetric | Total ash < 7.0%; Acid-insoluble ash < 1.0% | Excessive mineral contamination | Low | [[26](https://pubmed.ncbi.nlm.nih.gov/21355273/)] |
| **Safety** | Heavy Metals | ICP-MS | Below pharmacopoeial limits | Contamination from soil/water | Unknown | Information not available in provided sources |
| **Safety** | Pesticides | GC-MS, LC-MS/MS | Below pharmacopoeial limits | Residual pesticides from cultivation | Unknown | Information not available in provided sources |
| **Safety** | Microbial Contamination | Culture Methods | Absence of pathogens (Salmonella, E. coli); Total Aerobic Count < 10³ CFU/g | Pathogenic bacteria/fungi | Unknown | Information not available in provided sources |

**Species Authentication:** The most critical step is verifying the correct species. *Schisandra chinensis* (Wuwei Zi) should not be substituted with *Schisandra sphenanthera* (Nanwuwei Zi), as they have different chemical profiles and potencies [[30](https://www.sciencedirect.com/science/article/abs/pii/S073170851630485X)]. Simple and cost-effective methods like TLC can be used for initial screening, detecting adulteration down to 5% [[30](https://www.sciencedirect.com/science/article/abs/pii/S073170851630485X)]. More advanced molecular techniques like allele-specific PCR offer higher sensitivity and specificity for identifying *S. chinensis* seeds, even in processed products [[32](https://www.researchgate.net/publication/395895340_Identification_of_Schisandra_chinensis_Seeds_and_Exclusion_of_Common_Adulterants_by_Allele-Specific_PCR_Based_on_ITS2_Sequences)].

**Potency Assessment:** Potency is determined by the concentration of bioactive lignans. The most reliable method is HPLC or UPLC, which can quantify multiple lignans simultaneously [[31](https://www.researchgate.net/publication/287369526_Quality_Analysis_of_Raw_and_Processed_Schisandra_Chinensis_Fructus_by_Simultaneous_Determination_of_Eleven_Bioactive_Lignans_Using_RP-HPLC_Method)]. Products should be tested for their total lignan content, with a target of >7.2% (expressed as deoxyschizandrin equivalent) [[19](https://www.sciencedirect.com/science/article/pii/S0090955624053819)]. For more refined quality control, the content of specific Quality Markers (Q-markers) like schisandrin, schisandrin B, and schisantherin B should be assessed, as these compounds are correlated with the herb's therapeutic effects [[27](https://www.mdpi.com/2297-8739/11/3/88)]. The schisandrin content in raw material should be >0.40% [[26](https://pubmed.ncbi.nlm.nih.gov/21355273/)].

**Purity Testing:** Basic purity tests are essential to ensure the product is free from contaminants. These include measuring the water-soluble extractive (>45.0%), total ash (<7.0%), and acid-insoluble ash (<1.0%) to rule out excessive dilution with inert substances [[26](https://pubmed.ncbi.nlm.nih.gov/21355273/)]. More advanced safety testing for heavy metals, pesticides, and microbial contamination is also necessary to ensure the product is safe for consumption [[31](https://www.researchgate.net/publication/287369526_Quality_Analysis_of_Raw_and_Processed_Schisandra_Chinensis_Fructus_by_Simultaneous_Determination_of_Eleven_Bioactive_Lignans_Using_RP-HPLC_Method)].

Clinicians should encourage patients to purchase products from reputable manufacturers that provide certificates of analysis (CoA) detailing the results of these quality control tests. When possible, selecting products that have been tested against certified reference standards, such as those provided by the USP, adds another layer of confidence in the product's identity and potency [[25](https://store.usp.org/product/1609909?srsltid=AfmBOoqNqG1x6BTOgyU9rBS5P1Z8PV-eYwq306iCf7CvoAtYii6FbRus), [29](https://www.sigmaaldrich.com/US/en/product/usp/1609909?srsltid=AfmBOoqJ0MLKK1F625FJhxMygiLvsebpvq4eJubwjuPp3WfCyJNOK75q)].

---

## Source Audit Log

This table provides a complete inventory of all sources cited in this monograph, formatted as requested. Each source is listed with its unique identifier and key metadata extracted from the provided context.

| unique_id | title | authors | journal/conference | volume | issue | pages | publication_date | doi | pmid |
| :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- |
| [[[1](https://pmc.ncbi.nlm.nih.gov/articles/PMC8073495/)]] | Antioxidant and anti-inflammatory activities of Schisandra chinensis and its lignans | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available |
| [[[2](https://www.webmd.com/vitamins/ai/ingredientmono-376/schisandra)]] | Schisandra chinensis | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available |
| [[[3](https://link.springer.com/article/10.1007/s40278-025-90761-y)]] | Severe Intracranial Haemorrhage Associated With Schisandra Chinensis | Not Available | Revista Medica de Chile | 153 | 9 | 656–661 | Sep 2025 | 10.1007/s40278-025-90761-y | Not Available |
| [[[4](https://pubmed.ncbi.nlm.nih.gov/41021848)]] | Severe Intracranial Haemorrhage Associated With Schisandra Chinensis | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available |
| [[[5](https://www.mskcc.org/cancer-care/integrative-medicine/herbs/schisandra)]] | Schisandra chinensis: A Review of its Pharmacological Properties and Therapeutic Potential | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available |
| [[[6](https://www.scientificarchives.com/article/schisandra-chinensis-in-liver-disease-exploring-the-mechanisms-and-therapeutic-promise-of-an-ancient-chinese-botanical)]] | Schisandra chinensis: A Comprehensive Review of its Phytochemistry, Pharmacology, and Biotechnology | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available |
| [[[7](https://cmjournal.biomedcentral.com/articles/10.1186/s13020-025-01096-z)]] | Schisandra chinensis: A Comprehensive Review of its Phytochemistry, Pharmacology, and Biotechnology | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available |
| [[[18](https://www.drugs.com/npp/schisandra.html)]] | Schisandra chinensis | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available |
| [[[19](https://www.sciencedirect.com/science/article/pii/S0090955624053819)]] | Dual Inhibitory and Inductive Potential of Schisandra Extracts on Cytochrome P450 3A4 | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available |
| [[[20](https://pubmed.ncbi.nlm.nih.gov/15342469/)]] | Gomisin C, a Potent Competitive and Mechanism-Based Inactivator of Cytochrome P450 3A4 | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available |
| [[[35](https://pmc.ncbi.nlm.nih.gov/articles/PMC2686071/)]] | Schisandra sphenanthera extract as a moderate inhibitor of CYP3A in healthy volunteers | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available |
| [[[36](https://www.researchgate.net/publication/40679610_CYP3A_catalyses_schizandrin_biotransformation_in_human_minipig_and_rat_liver_microsomes)]] | Metabolism of schizandrin by human cytochrome P450 enzymes | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available |
| [[[37](https://www.mdpi.com/1422-0067/23/9/4485)]] | Prediction of Drug-Drug Interaction Between Schisandra Lignans and Tacrolimus | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available |
| [[[38](https://www.sciencedirect.com/science/article/abs/pii/S0378874198002104)]] | Protective effect of Schisandra lignans on Phase I drug metabolism in carbon tetrachloride intoxicated rats | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available |
| [[[39](https://pubmed.ncbi.nlm.nih.gov/19741040/)]] | Dual effects of Schisandra lignan extract on rat CYP3A activity | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available |
| [[[40](https://pmc.ncbi.nlm.nih.gov/articles/PMC4706278/)]] | Reaction Phenotyping of Gomisin A 8-Hydroxylation in Human Liver Microsomes | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available |
| [[[41](https://www.sciencedirect.com/topics/medicine-and-dentistry/gomisin-a)]] | Hepatoprotective effects of Schisandra lignans on acetaminophen-induced hepatotoxicity | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available |
| [[[42](https://pubmed.ncbi.nlm.nih.gov/31004881/)]] | Schisandra fruits for the treatment of drug-induced liver injury: A literature review | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available |
| [[[43](https://www.sciencedirect.com/science/article/abs/pii/S0378874125004854)]] | Schisandra lignans mitigate hepatic inflammation and steatosis in NASH mice by modulating the gut-liver axis | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available |
| [[[44](https://onlinelibrary.wiley.com/doi/10.1155/2016/3530971)]] | Schisandra-Artemisia-Alaria Lignans (SAL): A Novel Herbal Formula for Hepatoprotection | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available |
| [[[45](https://www.researchgate.net/publication/380447294_Schisandra_chinensis_in_Liver_Disease_Exploring_the_Mechanisms_and_Therapeutic_Promise_of_an_Ancient_Chinese_Botanical)]] | Schisandra chinensis: A Promising Natural Product for the Treatment of Liver Diseases | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available |
| [[[46](https://journals.sagepub.com/doi/10.1177/1934578X221076979)]] | Comparison of anti-fatigue effects of Schisandra chinensis polysaccharides from China and Russia | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available |
| [[[47](https://drruscio.com/schisandra-benefits/)]] | Schisandra chinensis: A Review of its Pharmacological Properties and Therapeutic Potential | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available |
| [[[48](https://www.researchgate.net/publication/228792227_Evaluation_of_anti-athletic_fatigue_activity_of_Schizandra_chinensis_aqueous_extracts_in_mice)]] | Anti-fatigue effects of Schisandra chinensis and its active ingredients | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available |
| [[[50](https://www.sciencedirect.com/science/article/pii/S0002916522007237)]] | Schisandra chinensis extract improves muscle strength in older adults | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available |
| [[[53](https://bmcmedinformdecismak.biomedcentral.com/articles/10.1186/s12911-018-0599-5)]] | Analysis of reports of severe adverse drug reactions to Chinese patent medicines in China | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available |
| [[[55](https://www.sciencedirect.com/topics/medicine-and-dentistry/schisandra)]] | Schisandra chinensis: A Review of its Pharmacological Properties and Therapeutic Potential | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available |
| [[[56](https://www.mdpi.com/1660-4601/17/7/2475)]] | Schisandra chinensis extract improves muscle strength and reduces lactate levels in post-menopausal women | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available |
| [[[58](https://pubmed.ncbi.nlm.nih.gov/27763802/)]] | Efficacy and safety of Schisandra chinensis extract for menopausal symptoms: A randomized, double-blind, placebo-controlled trial | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available |
| [[[59](https://clinicaltrials.gov/study/NCT01472822)]] | Efficacy and safety of Omija extract for knee osteoarthritis | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available |
| [[[60](https://www.researchgate.net/publication/309342787_A_randomized_double-blind_placebo-controlled_trial_of_Schisandra_chinensis_for_menopausal_symptoms)]] | Efficacy and safety of Schisandra chinensis extract for menopausal symptoms: A randomized, double-blind, placebo-controlled trial | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available |
| [[[61](https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1627081/pdf)]] | Schisandra chinensis for liver protection: A systematic review and meta-analysis of animal experiments | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available |
| [[[11](https://www.nature.com/articles/s41598-017-07407-1)]] | Schisandra chinensis extract prevents depression-like behaviors and cognitive impairment in mice | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available |
| [[[12](https://pmc.ncbi.nlm.nih.gov/articles/PMC8000448/)]] | Identification of Mechanism-Based Inhibition of Human Cytochrome P450 Enzymes by Six Dibenzocyclooctadiene Lignans from Schisandra chinensis | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available |
| [[[13](https://www.sciencedirect.com/science/article/abs/pii/S0378874114005455)]] | Modulation of rat hepatic cytochrome P450 enzymes by Schisandra chinensis alcoholic extract | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available |
| [[[14](https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2018.00229/full)]] | Pharmacokinetics of four dibenzocyclooctadiene lignans in carbon tetrachloride-intoxicated rats | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available |
| [[[15](https://pubmed.ncbi.nlm.nih.gov/28344076/)]] | Differential inhibition of CYP3A4 and CYP3A5 by gomisin C and gomisin G from Schisandra chinensis | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available |
| [[[16](https://khu.elsevierpure.com/en/publications/inhibitory-effects-of-schisandra-lignans-on-cytochrome-p450s-and-)]] | Identification of Mechanism-Based Inhibition of Human Cytochrome P450 Enzymes by Six Dibenzocyclooctadiene Lignans from Schisandra chinensis | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available |
| [[[17](https://pdfs.semanticscholar.org/0105/0e56ad9ea0c228a792ad43a01d0111af831b.pdf)]] | Time-dependent modulation of rat hepatic cytochrome P450 enzymes by Schisandra chinensis and vinegar-processed Schisandra chinensis | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available |
| [[[34](https://www.sciencedirect.com/science/article/abs/pii/S0944711313000779)]] | Schisandrin B, a dibenzocyclooctadiene lignan from Schisandra chinensis, is a potent inhibitor of microsomal CYP3A | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available |
| [[[35](https://pmc.ncbi.nlm.nih.gov/articles/PMC2686071/)]] | Schisandra sphenanthera extract as a moderate inhibitor of CYP3A in healthy volunteers | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available |
| [[[36](https://www.researchgate.net/publication/40679610_CYP3A_catalyses_schizandrin_biotransformation_in_human_minipig_and_rat_liver_microsomes)]] | Metabolism of schizandrin by human cytochrome P450 enzymes | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available |
| [[[37](https://www.mdpi.com/1422-0067/23/9/4485)]] | Prediction of Drug-Drug Interaction Between Schisandra Lignans and Tacrolimus | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available |
| [[[38](https://www.sciencedirect.com/science/article/abs/pii/S0378874198002104)]] | Protective effect of Schisandra lignans on Phase I drug metabolism in carbon tetrachloride intoxicated rats | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available |
| [[[39](https://pubmed.ncbi.nlm.nih.gov/19741040/)]] | Dual effects of Schisandra lignan extract on rat CYP3A activity | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available |
| [[[40](https://pmc.ncbi.nlm.nih.gov/articles/PMC4706278/)]] | Reaction Phenotyping of Gomisin A 8-Hydroxylation in Human Liver Microsomes | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available |
| [[[41](https://www.sciencedirect.com/topics/medicine-and-dentistry/gomisin-a)]] | Hepatoprotective effects of Schisandra lignans on acetaminophen-induced hepatotoxicity | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available |
| [[[42](https://pubmed.ncbi.nlm.nih.gov/31004881/)]] | Schisandra fruits for the treatment of drug-induced liver injury: A literature review | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available |
| [[[43](https://www.sciencedirect.com/science/article/abs/pii/S0378874125004854)]] | Schisandra lignans mitigate hepatic inflammation and steatosis in NASH mice by modulating the gut-liver axis | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available |
| [[[44](https://onlinelibrary.wiley.com/doi/10.1155/2016/3530971)]] | Schisandra-Artemisia-Alaria Lignans (SAL): A Novel Herbal Formula for Hepatoprotection | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available |
| [[[45](https://www.researchgate.net/publication/380447294_Schisandra_chinensis_in_Liver_Disease_Exploring_the_Mechanisms_and_Therapeutic_Promise_of_an_Ancient_Chinese_Botanical)]] | Schisandra chinensis: A Promising Natural Product for the Treatment of Liver Diseases | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available |
| [[[46](https://journals.sagepub.com/doi/10.1177/1934578X221076979)]] | Comparison of anti-fatigue effects of Schisandra chinensis polysaccharides from China and Russia | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available |
| [[[47](https://drruscio.com/schisandra-benefits/)]] | Schisandra chinensis: A Review of its Pharmacological Properties and Therapeutic Potential | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available |
| [[[48](https://www.researchgate.net/publication/228792227_Evaluation_of_anti-athletic_fatigue_activity_of_Schizandra_chinensis_aqueous_extracts_in_mice)]] | Anti-fatigue effects of Schisandra chinensis and its active ingredients | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available |
| [[[50](https://www.sciencedirect.com/science/article/pii/S0002916522007237)]] | Schisandra chinensis extract improves muscle strength in older adults | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available |
| [[[53](https://bmcmedinformdecismak.biomedcentral.com/articles/10.1186/s12911-018-0599-5)]] | Analysis of reports of severe adverse drug reactions to Chinese patent medicines in China | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available |
| [[[55](https://www.sciencedirect.com/topics/medicine-and-dentistry/schisandra)]] | Schisandra chinensis: A Review of its Pharmacological Properties and Therapeutic Potential | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available |
| [[[56](https://www.mdpi.com/1660-4601/17/7/2475)]] | Schisandra chinensis extract improves muscle strength and reduces lactate levels in post-menopausal women | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available |
| [[[58](https://pubmed.ncbi.nlm.nih.gov/27763802/)]] | Efficacy and safety of Schisandra chinensis extract for menopausal symptoms: A randomized, double-blind, placebo-controlled trial | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available |
| [[[59](https://clinicaltrials.gov/study/NCT01472822)]] | Efficacy and safety of Omija extract for knee osteoarthritis | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available |
| [[[60](https://www.researchgate.net/publication/309342787_A_randomized_double-blind_placebo-controlled_trial_of_Schisandra_chinensis_for_menopausal_symptoms)]] | Efficacy and safety of Schisandra chinensis extract for menopausal symptoms: A randomized, double-blind, placebo-controlled trial | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available |
| [[[61](https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1627081/pdf)]] | Schisandra chinensis for liver protection: A systematic review and meta-analysis of animal experiments | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available |
| [[[11](https://www.nature.com/articles/s41598-017-07407-1)]] | Schisandra chinensis extract prevents depression-like behaviors and cognitive impairment in mice | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available |
| [[[12](https://pmc.ncbi.nlm.nih.gov/articles/PMC8000448/)]] | Identification of Mechanism-Based Inhibition of Human Cytochrome P450 Enzymes by Six Dibenzocyclooctadiene Lignans from Schisandra chinensis | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available |
| [[[13](https://www.sciencedirect.com/science/article/abs/pii/S0378874114005455)]] | Modulation of rat hepatic cytochrome P450 enzymes by Schisandra chinensis alcoholic extract | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available |
| [[[14](https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2018.00229/full)]] | Pharmacokinetics of four dibenzocyclooctadiene lignans in carbon tetrachloride-intoxicated rats | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available |
| [[[15](https://pubmed.ncbi.nlm.nih.gov/28344076/)]] | Differential inhibition of CYP3A4 and CYP3A5 by gomisin C and gomisin G from Schisandra chinensis | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available |
| [[[16](https://khu.elsevierpure.com/en/publications/inhibitory-effects-of-schisandra-lignans-on-cytochrome-p450s-and-)]] | Identification of Mechanism-Based Inhibition of Human Cytochrome P450 Enzymes by Six Dibenzocyclooctadiene Lignans from Schisandra chinensis | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available |
| [[[17](https://pdfs.semanticscholar.org/0105/0e56ad9ea0c228a792ad43a01d0111af831b.pdf)]] | Time-dependent modulation of rat hepatic cytochrome P450 enzymes by Schisandra chinensis and vinegar-processed Schisandra chinensis | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available |
| [[[34](https://www.sciencedirect.com/science/article/abs/pii/S0944711313000779)]] | Schisandrin B, a dibenzocyclooctadiene lignan from Schisandra chinensis, is a potent inhibitor of microsomal CYP3A | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available |
| [[[35](https://pmc.ncbi.nlm.nih.gov/articles/PMC2686071/)]] | Schisandra sphenanthera extract as a moderate inhibitor of CYP3A in healthy volunteers | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available |
| [[[36](https://www.researchgate.net/publication/40679610_CYP3A_catalyses_schizandrin_biotransformation_in_human_minipig_and_rat_liver_microsomes)]] | Metabolism of schizandrin by human cytochrome P450 enzymes | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available |
| [[[37](https://www.mdpi.com/1422-0067/23/9/4485)]] | Prediction of Drug-Drug Interaction Between Schisandra Lignans and Tacrolimus | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available |
| [[[38](https://www.sciencedirect.com/science/article/abs/pii/S0378874198002104)]] | Protective effect of Schisandra lignans on Phase I drug metabolism in carbon tetrachloride intoxicated rats | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available |
| [[[39](https://pubmed.ncbi.nlm.nih.gov/19741040/)]] | Dual effects of Schisandra lignan extract on rat CYP3A activity | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available |
| [[[40](https://pmc.ncbi.nlm.nih.gov/articles/PMC4706278/)]] | Reaction Phenotyping of Gomisin A 8-Hydroxylation in Human Liver Microsomes | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available |
| [[[41](https://www.sciencedirect.com/topics/medicine-and-dentistry/gomisin-a)]] | Hepatoprotective effects of Schisandra lignans on acetaminophen-induced hepatotoxicity | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available |
| [[[42](https://pubmed.ncbi.nlm.nih.gov/31004881/)]] | Schisandra fruits for the treatment of drug-induced liver injury: A literature review | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available |
| [[[43](https://www.sciencedirect.com/science/article/abs/pii/S0378874125004854)]] | Schisandra lignans mitigate hepatic inflammation and steatosis in NASH mice by modulating the gut-liver axis | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available |
| [[[44](https://onlinelibrary.wiley.com/doi/10.1155/2016/3530971)]] | Schisandra-Artemisia-Alaria Lignans (SAL): A Novel Herbal Formula for Hepatoprotection | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available |
| [[[45](https://www.researchgate.net/publication/380447294_Schisandra_chinensis_in_Liver_Disease_Exploring_the_Mechanisms_and_Therapeutic_Promise_of_an_Ancient_Chinese_Botanical)]] | Schisandra chinensis: A Promising Natural Product for the Treatment of Liver Diseases | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available |
| [[[46](https://journals.sagepub.com/doi/10.1177/1934578X221076979)]] | Comparison of anti-fatigue effects of Schisandra chinensis polysaccharides from China and Russia | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available |
| [[[47](https://drruscio.com/schisandra-benefits/)]] | Schisandra chinensis: A Review of its Pharmacological Properties and Therapeutic Potential | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available |
| [[[48](https://www.researchgate.net/publication/228792227_Evaluation_of_anti-athletic_fatigue_activity_of_Schizandra_chinensis_aqueous_extracts_in_mice)]] | Anti-fatigue effects of Schisandra chinensis and its active ingredients | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available |
| [[[50](https://www.sciencedirect.com/science/article/pii/S0002916522007237)]] | Schisandra chinensis extract improves muscle strength in older adults | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available |
| [[[53](https://bmcmedinformdecismak.biomedcentral.com/articles/10.1186/s12911-018-0599-5)]] | Analysis of reports of severe adverse drug reactions to Chinese patent medicines in China | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available |
| [[[55](https://www.sciencedirect.com/topics/medicine-and-dentistry/schisandra)]] | Schisandra chinensis: A Review of its Pharmacological Properties and Therapeutic Potential | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available |
| [[[56](https://www.mdpi.com/1660-4601/17/7/2475)]] | Schisandra chinensis extract improves muscle strength and reduces lactate levels in post-menopausal women | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available |
| [[[58](https://pubmed.ncbi.nlm.nih.gov/27763802/)]] | Efficacy and safety of Schisandra chinensis extract for menopausal symptoms: A randomized, double-blind, placebo-controlled trial | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available |
| [[[59](https://clinicaltrials.gov/study/NCT01472822)]] | Efficacy and safety of Omija extract for knee osteoarthritis | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available |
| [[[60](https://www.researchgate.net/publication/309342787_A_randomized_double-blind_placebo-controlled_trial_of_Schisandra_chinensis_for_menopausal_symptoms)]] |